Latest Insider Transactions at Titan Pharmaceuticals Inc (TTNP)
This section provides a real-time view of insider transactions for Titan Pharmaceuticals Inc (TTNP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TITAN PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TITAN PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Choon Hau Choong > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
54,132
+1.4%
|
-
|
|
Oct 25
2023
|
Eric Howard Greenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Matthew Charles Mc Murdo Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
David Natan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Katherine Beebe President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Oct 25
2023
|
Avraham Ben Tzvi Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+19.7%
|
-
|
|
Jul 26
2023
|
Eric Howard Greenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
David E. Lazar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jul 26
2023
|
Avraham Ben Tzvi Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Katherine Beebe President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Peter Louis Chasey Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
David Natan Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 26
2023
|
Matthew Charles Mc Murdo Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jun 21
2023
|
David E. Lazar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
359,066
-100.0%
|
$359,066
$1.23 P/Share
|
|
Jun 21
2023
|
David E. Lazar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,388,902
-100.0%
|
$3,388,902
$1.23 P/Share
|
|
Jan 25
2023
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+0.59%
|
$20,000
$1.0 P/Share
|
|
Jan 24
2023
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
37,500
+1.1%
|
$0
$0.97 P/Share
|
|
Jul 07
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
744,294
+18.26%
|
$0
$0.99 P/Share
|
|
Jul 06
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
315,921
+46.8%
|
$0
$0.89 P/Share
|
|
Jul 06
2022
|
David E. Lazar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,165,975
+31.07%
|
$0
$0.77 P/Share
|
|
Jan 28
2022
|
James R Mcnab Director |
BUY
Other acquisition or disposition
|
Indirect |
51,021
+50.0%
|
-
|